In another example of non-core asset disposals by pharmaceutical groups, France’s Sanofi reportedly is looking to offload a portfolio of drugs that could be valued at between US$7bn and US$8bn…
Sanofi looks to shed portfolio
Would you like to read this article?
Register below to continue reading this article.
You will be able to read 2 articles. No payment details required.
You will also receive our daily M&A insights email.
There is no obligation to subscribe to the service but we hope that after the trialing your firm will decide to subscribe.
For details of subscription packages or if you are considering a subscription and would like to read a few more articles on your trial, please contact us at email@example.com and we will call you to discuss.
Already a subscriber? Login here